IMCL Insider Trading Activity and SEC Form 4 Filings
IMCL insider trading summary
No open-market insider purchases or sales of Immunoclin Corp (IMCL) have been reported on SEC Form 4 in the past 12 months.
Latest IMCL insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jan 30, 2015 | Castor Management Services Inc. | 10% Owner | Sell | $10K (10,000,000 @ $0.00) |
| Jan 30, 2015 | Castor Management Services Inc. | 10% Owner | Sell | $500 (500,000 @ $0.00) |
| Nov 21, 2008 | Beckton Corp | 10% Owner | Sell | $816.9M (11,669,544 @ $70.00) |
| Nov 21, 2008 | Barberry Corp. | 10% Owner | Sell | $816.9M (11,669,544 @ $70.00) |
| Nov 21, 2008 | Hopper Investments LLC | 10% Owner | Sell | $816.9M (11,669,544 @ $70.00) |
| Nov 21, 2008 | Carl C Icahn | Director | Sell | $816.9M (11,669,544 @ $70.00) |
| Nov 21, 2008 | High River Limited Partnership | 10% Owner | Sell | $816.9M (11,669,544 @ $70.00) |
| Nov 21, 2008 | Icahn Enterprises Holdings L.P. | 10% Owner | Sell | $816.9M (11,669,544 @ $70.00) |
| Nov 21, 2008 | Icahn Enterprises G.p. Inc. | 10% Owner | Sell | $816.9M (11,669,544 @ $70.00) |
| Nov 3, 2008 | Richard CROWLEY | SVP, Biopharmaceutical Ops | Sell | $822K (11,957 @ $68.72) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.